LJ501-CRH01: A phase 3, placebo-controlled, randomized, double-blind, multi-center study of LJPC-501 in patients with catecholamine-resistant hypotension (CRH),
Role: Investigator,
La Jolla Pharmaceutical Company,
(02/2017 - 02/2018)
Status: Completed
OASIS: A phase 2/3 randomized, double-blind, placebo-controlled, study of the safety and efficacy of talactoferrin alfa in patients with severe sepsis,
Role: Investigator,
Agennix, Inc.,
(05/2012 - 05/2013)
Status: Completed
A phase 2 study to evaluate dose and duration of treatment of drotrecogin alfa (activated) using serial measurements of protein C in patients with severe and multiple organ dysfunctions,
Role: Investigator,
Eli Lilly & Co.,
(11/2008 - 11/2009)
Status: Completed
Internal
The effects of upper airway resistance syndrome on executive function,
Role: Investigator,
LLU Dept. of Medicine,
(03/2022)
Status: Approved
Etiologies of Apnea of Infancy (AOI): A Follow Up Study,
Role: Investigator,
LLU Dept. of Pediatrics,
(01/2022)
Status: Approved
Clinical factors that would predict the diagnosis and severity of sleep disordered breathing (SDB) which includes OSA, and Sleep related hypoxemia in Patients with Interstitial Lung Disease (ILD),
Role: Investigator,
LLU Dept. of Medicine,
(07/2021)
Status: Approved